Bioequivalence Study of Two Imatinib Formulations after Single-dose Administration in Healthy Korean Male Volunteers

Abstract

Objective:

Imatinib mesylate is effective for chronic myeloid leukaemia and gastrointestinal tumours. We aimed to evaluate the pharmacokinetics of a 200-mg imatinib tablet compared to 2×100-mg imatinib tablets in order to meet the regulatory requirements for marketing in Korea.

Methods:

An open-label, randomized, single-dose, 2-period, 2-treatment cross-over study was conducted in 28 healthy Korean male volunteers. Subjects were administered a 200-mg imatinib tablet and 2×100-mg imatinib tablets under a fasting state according to a randomly assigned order with a 2-week wash-out period. Serial blood samples were collected up to 72 h post-dose. The pharmacokinetic parameters were calculated using non-compartmental methods.

Results:

A total of 28 subjects were enrolled and 23 subjects completed the study. There were no serious adverse events during the study. 23 mild to moderate adverse events were reported (11 events with 200-mg imatinib vs. 12 events with 2×100-mg imatinib) and subjects recovered without sequelae. The C_max value was 922.8±318.8 μg/L at 3.15 h for 200-mg imatinib tablet, and 986.3±266.0 μg/L at 2.91 h for the 2×100-mg imatinib tablet. The AUC_last of 200-mg and 2×100-mg tablets were 13 084.3±39.1 and 14 131.7±3 826.2 h · μg/L, respectively. The geometric mean ratios (90% confidence intervals) for C_max and AUC_last were 0.9121 (0.8188, 1.0161) and 0.9558 (0.8685, 1.0519), respectively.

Conclusion:

A newly developed 200-mg imatinib tablet was bioequivalent to 2×100-mg imatinib tablets in healthy Korean subjects. A single-dose of either of the 2 formulations was generally well tolerated.

Key words

bioequivalence - imatinib - Korean - pharmacokinetics

• References

• 1 Din OS, Woll PJ. Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther Clin Risk Manag 2008; 4: 149-162
• 2 Baccarani M, Rosti G, de Vivo A et al Italian Cooperative Study Group on Myeloid Leukemia. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002; 99: 1527-1535
• 3 Guilhot F, Chastang C, Michallet M et al French Chronic Myeloid Leukemia Study Group . Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Eng J Med 1997; 337: 223-229
• 4 O’Brien SG, Guilhot F, Larson RA et al IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med 2003; 348: 994-1004
• 5 Druker BJ, Guilhot F, O’Brien SG et al IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Eng J Med 2006; 355: 2408-2417
• 6 Cortes J, Giles F, O’Brien S et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood 2003; 102: 83-86
• 7 US Food and Drug Administration . Gleevec (imatinib mesylate) tablets for oral use label. 2013;
• 8 Korea Food and Drug Administration . Imatinib mesylate label. 2001;
• 9 Kuypers DR, Peeters PC, Sennesael JJ. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation 2013; 95: 333-340
• 10 Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev 2012; 14: 168-178
• 11 Guilhot F, Hughes TP, Cortes J et al. Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial. Haematologica 2012; 97: 731-738
• 12 Peng B, Hayes M, Resta D et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935-942
• 13 Nikolova Z, Peng B, Hubert M et al. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemotherapy and Pharmacology 2004; 53: 433-438
• 14 Yang JS, Cho EG, Huh W et al. Rapid determination of imatinib in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Bull Korean Chem Soc 2013; 34: 2425-2430
• 15 Johan Gabrielsson DW. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 4^th Edition Sweden: Apotekarsocieteten; 2006
• 16 Parrillo-Campiglia S, Ercoli MC, Umpierrez O et al. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clin Ther 2009; 31: 2224-2232
• 17 Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn 2001; 28: 155-169
• 18 National Institute of Toxicological Research . Minimum requirements for bioequivalence test 2005;
• 19 US Food and Drug Administration . Guidance for Industry, Bioequivalence guidance. 2006;
• 20 Peng B, Dutreix C, Mehring G et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. Journal of clinical pharmacology 2004; 44: 158-162
• 21 Dutreix C, Peng B, Mehring G et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer chemotherapy and pharmacology 2004; 54: 290-294
• 22 Schmidli H, Peng B, Riviere GJ et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. British journal of clinical pharmacology 2005; 60: 35-44
• 23 Lee JP, Birnstein E, Masiello D et al. Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. Journal of hematology & oncology 2009; 2: 30